Lenalidomide

Revlimid (lenalidomide) is a small molecule pharmaceutical. Lenalidomide was first approved as Revlimid on 2005-12-27. It is used to treat b-cell lymphoma marginal zone, follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes in the USA. It has been approved in Europe to treat follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes. The pharmaceutical is active against protein cereblon. Revlimid's patents are valid until 2028-03-08 (FDA).